PL364111A1 - Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk) - Google Patents
Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk)Info
- Publication number
- PL364111A1 PL364111A1 PL02364111A PL36411102A PL364111A1 PL 364111 A1 PL364111 A1 PL 364111A1 PL 02364111 A PL02364111 A PL 02364111A PL 36411102 A PL36411102 A PL 36411102A PL 364111 A1 PL364111 A1 PL 364111A1
- Authority
- PL
- Poland
- Prior art keywords
- ikk
- inhibitors
- methods
- treating inflammatory
- immune diseases
- Prior art date
Links
- 102000001284 I-kappa-B kinase Human genes 0.000 title 1
- 108060006678 I-kappa-B kinase Proteins 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26585301P | 2001-02-01 | 2001-02-01 | |
US09/965,977 US6960585B2 (en) | 2000-10-03 | 2001-09-27 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
PCT/US2002/003060 WO2002060386A2 (en) | 2001-02-01 | 2002-02-01 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) |
Publications (1)
Publication Number | Publication Date |
---|---|
PL364111A1 true PL364111A1 (en) | 2004-12-13 |
Family
ID=26951465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL02364111A PL364111A1 (en) | 2001-02-01 | 2002-02-01 | Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk) |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1363993A4 (cs) |
JP (1) | JP2004529088A (cs) |
AU (1) | AU2002247059B2 (cs) |
CA (1) | CA2436770A1 (cs) |
CZ (1) | CZ20032287A3 (cs) |
HU (1) | HUP0304045A3 (cs) |
MX (1) | MXPA03006817A (cs) |
NO (1) | NO20033429L (cs) |
PL (1) | PL364111A1 (cs) |
WO (1) | WO2002060386A2 (cs) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2424303A1 (en) * | 2000-10-03 | 2002-04-11 | Bristol-Myers Squibb Company | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
JP4285602B2 (ja) | 2000-10-26 | 2009-06-24 | アムジェン インコーポレイテッド | 抗炎症剤 |
WO2003048152A2 (en) | 2001-12-05 | 2003-06-12 | Tularik Inc. | Inflammation modulators |
DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | ANTI-INFLAMMATORY AGENTS |
PE20060373A1 (es) | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
PE20060748A1 (es) | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
MX2007016541A (es) | 2005-06-30 | 2008-03-07 | Smithkline Beecham Corp | Compuestos quimicos. |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
WO2007030362A1 (en) * | 2005-09-07 | 2007-03-15 | Laboratoires Serono Sa. | Ikk inhibitors for the treatment of endometriosis |
US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
US8299080B2 (en) * | 2006-12-13 | 2012-10-30 | Aska Pharmaceutical Co., Ltd. | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
CA2721927C (en) | 2008-04-21 | 2014-01-28 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
WO2010000903A2 (es) * | 2008-06-30 | 2010-01-07 | Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) | Composición capaz de modular la actividad de ikkalpha para el tratamiento de enfermedades que cursan con acantolisis |
JP5312466B2 (ja) | 2008-10-02 | 2013-10-09 | 旭化成ファーマ株式会社 | 8位置換イソキノリン誘導体及びその用途 |
EP2406249A1 (en) | 2009-03-10 | 2012-01-18 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
EP3478269A4 (en) | 2016-06-29 | 2020-04-08 | Otonomy, Inc. | OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES |
EP3494994A1 (en) * | 2017-12-07 | 2019-06-12 | Universität zu Köln | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4160097A (en) * | 1977-01-07 | 1979-07-03 | Westwind Pharmaceuticals, Inc. | 1-(2-Phenylureylene)imidazoles |
US5851812A (en) * | 1997-07-01 | 1998-12-22 | Tularik Inc. | IKK-β proteins, nucleic acids and methods |
US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US6030834A (en) * | 1997-12-30 | 2000-02-29 | Chiron Corporation | Human IKK-beta DNA constructs and cells |
GB0003154D0 (en) * | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
DE60141895D1 (de) * | 2000-03-15 | 2010-06-02 | Sanofi Aventis Deutschland | Substituierte beta-carboline mit ikb-kinase hemmender wirkung |
CA2424303A1 (en) * | 2000-10-03 | 2002-04-11 | Bristol-Myers Squibb Company | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
-
2002
- 2002-02-01 HU HU0304045A patent/HUP0304045A3/hu unknown
- 2002-02-01 EP EP02714815A patent/EP1363993A4/en not_active Withdrawn
- 2002-02-01 MX MXPA03006817A patent/MXPA03006817A/es active IP Right Grant
- 2002-02-01 AU AU2002247059A patent/AU2002247059B2/en not_active Ceased
- 2002-02-01 CZ CZ20032287A patent/CZ20032287A3/cs unknown
- 2002-02-01 WO PCT/US2002/003060 patent/WO2002060386A2/en active Application Filing
- 2002-02-01 PL PL02364111A patent/PL364111A1/xx not_active Application Discontinuation
- 2002-02-01 JP JP2002560582A patent/JP2004529088A/ja active Pending
- 2002-02-01 CA CA002436770A patent/CA2436770A1/en not_active Abandoned
-
2003
- 2003-07-31 NO NO20033429A patent/NO20033429L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1363993A4 (en) | 2008-11-12 |
AU2002247059B2 (en) | 2006-11-16 |
JP2004529088A (ja) | 2004-09-24 |
WO2002060386A2 (en) | 2002-08-08 |
MXPA03006817A (es) | 2003-11-13 |
NO20033429L (no) | 2003-09-24 |
NO20033429D0 (no) | 2003-07-31 |
EP1363993A2 (en) | 2003-11-26 |
CZ20032287A3 (cs) | 2004-02-18 |
HUP0304045A2 (hu) | 2004-04-28 |
CA2436770A1 (en) | 2002-08-08 |
WO2002060386A3 (en) | 2002-10-10 |
HUP0304045A3 (en) | 2005-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL364111A1 (en) | Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk) | |
IL158550A0 (en) | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | |
EP1383743A4 (en) | DOUBLE INHIBITORS OF PDE 7 AND PDE 4 | |
IL161258A0 (en) | Heterocyclic compounds and methods of use | |
PL367272A1 (en) | Novel substituted benzimidazole dosage forms and method of using same | |
GB2393202B (en) | Methods of well treatment | |
AU2002364364A8 (en) | Method of treating apoptosis and compositions thereof | |
ZA200305825B (en) | Modified antibodies and methods of use | |
EP1390014A4 (en) | COMPOSITION AND METHODS FOR TREATING HYPERPLASIA | |
EP1363702A4 (en) | PROCESS FOR INHIBITING KINASES | |
MXPA03006420A (es) | Diaminotiazoles. | |
GB2373565B (en) | Detonation transfer subassembly and method for use of the same | |
PL353535A1 (en) | Application of selective pde 10 inhibitor and application of papaverine | |
NO20041345L (no) | Kopolymerer for undertrykkelse av autoimmune sykdommer og fremgangsmate for anvendelse | |
AU8136801A (en) | Methods of preventing or treating diseases and conditions using complex carbohydrates | |
NO20033854D0 (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
EP1372654A4 (en) | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | |
AU2003210983A8 (en) | Kinase inhibitors and methods of use thereof | |
IL155174A0 (en) | Methods and compositions for the treatment of inflammatory diseases | |
AU2002363938A8 (en) | Methods and use of motoneuronotropic factors | |
GB0124124D0 (en) | Methods of treatment | |
EP1472273A4 (en) | COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES | |
IL162481A0 (en) | Method and use of determining genotype | |
AU2002342715A1 (en) | Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors | |
EP1450849A4 (en) | METHOD FOR TREATING ENDOMETREOSE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |